研究药物干预易损斑块的作用及机制对临床防治急性冠脉综合征有重要意义。项目组前期研究发现，源于云南特色药用植物叶下珠的活性成分-Corilagin具有良好的抗血栓和抗动脉粥样硬化作用，并显示出潜在的稳定斑块作用。在此基础上，拟复制小型猪易损斑块模型，研究不同剂量的Corilagin治疗易损斑块的药理作用及其剂量-效应关系；在整体动物和体外培养的巨噬细胞模型上，寻找干预易损斑块形成发展的关键基因及其相互关系，研究Corilagin对CD40-CD40L信号通路关键因子的调控作用机制。以期从整体动物、易损斑块组织、细胞和分子水平系统研究Corilagin治疗易损斑块的作用，探索其细胞分子生物学机制，为将Corilagin研究成为自主创新和云南特色植物来源的治疗急性冠脉综合征药物提供进一步的理论和实验依据。

To study the effect and mechanism of drug on intervening vulnerable plaque is of great significance for clinical preventing and curing acute coronary syndrome（ACS）. Our previous researches showed that Corilagin, an active ingredient from Yunnan featured medicinal plant Phyllanthus, had obvious effects against the experimental thrombosis and atherosclerosis and showed a potential effect on stabilizing vulnerable plaque. Based on these results, the atherosclerotic model of high fatty diet combined with balloon injury in miniature swine will be duplicated to evaluate the effects of Corilagin on atherosclerotic vulnerable plaques and its dose-effect relationships; in vitro, macrophages model are prepared and the intervening links of key genes involved in vulnerable plaque development will be investigated both in animal model and cell model; the modulation of Corilagin on CD40-CD40L signal pathway will be also determined in atherosclerotic vulnerable plaques and the cultured cells through the detection of key signaling molecules. The interventional effects on atherosclerotic vulnerable plaques of Corilagin will be explored systematically at these different levels such as model animals, vulnerable plaques, cells and molecules, in order to provide more scientific bases and experimental evidences for curing ACS with Corilagin.